Munich
Germany
38
2026-05-14
The entities that hold a legal rights for patent applications filed by inventor Lutterbüse Ralf:
Ralf Lutterbüse from Munich, DE has applied for patents for these inventions. The list has both pending applications and granted patents:
ANTIBODY CONSTRUCTS FOR DLL3 AND CD3
#2 | 2026-04-30CROSS-SPECIES-SPECIFIC PSCAXCD3, CD19XCD3, C-METXCD3, ENDOSIALINXCD3, EPCAMXCD3, IGF-1RXCD3 OR FAPALPHAXCD3 BISPECIFIC SINGLE CHAIN ANTIBODY
#3 | 2025-11-06ANTIBODY CONSTRUCTS FOR DLL3 AND CD3
#4 | 2025-03-20BISPECIFIC ANTIBODY CONSTRUCTS FOR CDH3 AND CD3
#5 | 2024-05-23Single chain binding molecules comprising N-terminal ABP
#6 | 2024-01-11Antibody Constructs for CDH19 and CD3
#7 | 2023-10-05ANTIBODY CONSTRUCTS FOR DLL3 AND CD3
#8 | 2023-02-23LONG LIFE POLYPEPTIDE BINDING MOLECULES
#9 | 2023-02-09Bispecific antibody constructs for CDH3 and CD3
#10 | 2022-02-10Cross-species-specific single domain bispecific single chain antibody
#11 | 2021-10-07Antibody constructs for DLL3 and CD3
#12 | 2021-09-16ANTIBODY CONSTRUCTS FOR CD70 AND CD3
#13 | 2020-11-19CROSS-SPECIES-SPECIFIC PSCAXCD3, CD19XCD3, C-METXCD3, ENDOSIALINXCD3, EPCAMXCD3, IGF-1RXCD3 OR FAPALPHAXCD3 BISPECIFIC SINGLE CHAIN ANTIBODY
#14 | 2020-10-22Antibody constructs for DLL3 and CD3
#15 | 2020-03-26CROSS-SPECIES-SPECIFIC BISPECIFIC BINDERS
#16 | 2020-03-05ANTIBODY CONSTRUCTS FOR CDH19 AND CD3
#17 | 2020-02-06Single chain binding molecules comprising N-terminal ABP
#18 | 2019-08-29Antibody constructs for DLL3 and CD3
#19 | 2019-06-06CROSS-SPECIES-SPECIFIC PSMAxCD3 BISPECIFIC SINGLE CHAIN ANTIBODY
#20 | 2019-06-06LONG LIFE POLYPEPTIDE BINDING MOLECULES
#21 | 2019-01-17Antibody constructs for CDH19 and CD3
#22 | 2018-05-24Bispecific antibody constructs for CDH3 and CD3
#23 | 2018-01-04Antibody constructs for CDH19 and CD3
#24 | 2017-12-07Optimized cross-species specific bispecific single chain antibody contructs
#25 | 2017-05-18Pharmaceutical compositions with resistance to soluble CEA
#26 | 2017-05-11Antibody constructs for CD70 and CD3
#27 | 2017-02-09Antibody constructs for DLL3 and CD3
#28 | 2016-06-02CROSS-SPECIES-SPECIFIC BISPECIFIC BINDERS
#29 | 2016-02-04Antibody constructs for CDH19 and CD3
#30 | 2015-12-24Antibody constructs for CDH19 and CD3
#31 | 2014-10-30Antibody Constructs for CDH19 and CD3
#32 | 2012-02-09CROSS-SPECIES-SPECIFIC PSCAxCD3, CD19xCD3, C-METxCD3, ENDOSIALINxCD3, EPCAMxCD3, IGF-1RxCD3 OR FAPALPHAxCD3 BISPECIFIC SINGLE CHAIN ANTIBODY
#33 | 2011-12-01CROSS-SPECIES-SPECIFIC PSMAxCD3 BISPECIFIC SINGLE CHAIN ANTIBODY
#34 | 2011-11-10Cross-species-specific single domain bispecific single chain antibody
#35 | 2008-10-14Method of identifying binding site domains that retain the capacity of binding to an epitope
#36 | 2007-05-31Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders
#37 | 2006-09-26CD 19×CD3 specific polypeptides and uses thereof
#38 | 2006-08-31CD19xCD3 specific polypeptides and uses thereof
952721 ⎘